Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 6/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.42 |
| ▸ | PARP1 | P09874 | 2/20 | 0.37 |
| ▸ | CHEK1 | O14757 | 3/20 | 0.37 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 2/20 | 0.34 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | ATIC | P31939 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30159669 | 0.80 | KDM4E (0.48) | ROCK2MAPK14PARP1CHEK1KDM4E | |
| SCHEMBL2116289 | 0.80 | KDM4E (0.48) | ROCK2MAPK14PARP1CHEK1KDM4E | |
| SCHEMBL17277754 | 0.78 | SLC2A1 (0.54) | ROCK2MAPK14PARP1CHEK1SLC2A1 | |
| SCHEMBL6642826 | 0.75 | POLB (0.39) | SMN1; SMN2KDM4E | |
| SCHEMBL1145075 | 0.74 | KDM4E (0.61) | ROCK2MAPK14PARP1CHEK1KDM4E | |
| SCHEMBL30159472 | 0.74 | KDM4E (0.61) | ROCK2MAPK14PARP1CHEK1KDM4E | |
| SCHEMBL2118663 | 0.73 | MAPK14 (0.50) | ROCK2MAPK14PARP1CHEK1 | |
| SCHEMBL12647234 | 0.72 | MAPK14 (0.44) | ROCK2MAPK14PARP1CHEK1SMN1; SMN2 | |
| SCHEMBL986740 | 0.72 | KDM4E (0.58) | SMN1; SMN2KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL12663938 | 0.72 | MAPK14 (0.44) | ROCK2MAPK14PARP1CHEK1SLC2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080090860-A1 | Retinoid x receptor modulators | GARDINIER KEVIN M | 2008-04-17 | — | — | US | disclosed |
| US-20080090860-A1 | Retinoid x receptor modulators | GARDINIER KEVIN M | 2008-04-17 | — | — | US | disclosed |
| US-20080090860-A1 | Retinoid x receptor modulators | GARDINIER KEVIN M | 2008-04-17 | — | — | US | disclosed |
| US-7348359-B2 | Retinoid X receptor modulators | ELI LILLY AND COMPANY (US) | 2008-03-25 | — | — | US | disclosed |
| US-7348359-B2 | Retinoid X receptor modulators | ELI LILLY AND COMPANY (US) | 2008-03-25 | — | — | US | disclosed |
| US-7348359-B2 | Retinoid X receptor modulators | ELI LILLY AND COMPANY (US) | 2008-03-25 | — | — | US | disclosed |
| EP-1373240-B1 | RETINOID X RECEPTOR MODULATORS | LILLY CO ELI (US) | 2005-06-15 | — | — | EP | disclosed |
| US-20040167160-A1 | Retinoid x receptor modulators | LIGAND PHARMACEUTICALS INCORPORATED | 2004-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040167160-A1 | Retinoid x receptor modulators | RXRA, RXRG, RXRB | ROCK2 2127/4885MAPK14 3985/4885PARP1 4760/4885 |
| US-20080090860-A1 | Retinoid x receptor modulators | RXRA, RXRG, RXRB | ROCK2 2036/4885MAPK14 3804/4885PARP1 4628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.